Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03477513 · ClinicalTrials.gov registry record · NA

Personalized Radiation Therapy for GBM

A NA study of Glioblastoma, sponsored by Abramson Cancer Center at Penn Medicine.

Active
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03477513 is a NA study of Glioblastoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03477513, a NA study of Glioblastoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Conditions Studied

Interventions

  • RADIATION Radation Therapy

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-03-01
Est. Completion 2026-07-30
Phase NA

What the Registry Record Tells You About NCT03477513

The ClinicalTrials.gov registry entry for NCT03477513 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Radation Therapy is the first listed.

NCT03477513 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03477513 about?

NCT03477513 is a clinical study titled "Personalized Radiation Therapy for GBM". The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoint...

What is the current status of trial NCT03477513?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2018-03-01. Estimated completion is 2026-07-30.

What conditions does trial NCT03477513 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT03477513?

The interventions under investigation include: Radation Therapy (RADIATION).

Who is sponsoring clinical trial NCT03477513?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03477513 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.